Home Lack of consistency between two commercial ELISAs and against an in-house ELISA for the detection of CD36 in human plasma
Article
Licensed
Unlicensed Requires Authentication

Lack of consistency between two commercial ELISAs and against an in-house ELISA for the detection of CD36 in human plasma

  • Simon Lykkeboe EMAIL logo , Anne Lone Larsen and Aase Handberg
Published/Copyright: February 3, 2012

Abstract

Background: CD36 is a widely expressed cell surface receptor, that among other ligands binds lipoproteins, and its function has been implicated in many of the complications belonging to the metabolic syndrome. We have previously identified a circulating form of CD36 and established an in-house ELISA assay for measurement of CD36 in plasma. Plasma CD36 was elevated in insulin resistant obese and diabetic patients, and in patients with unstable atherosclerotic plaques. The objective of this study was to compare two new commercial CD36 ELISA assays and our in-house ELISA assay.

Methods: CD36 was measured in 30 plasma samples from 10 individuals by the in-house and the two commercial assays (Cusabio Biotech and Adipobioscience).

Results: Our results demonstrate that there is an absolute incongruity between the three assays. The incongruity could not be explained by different pre-analytical procedures in assay protocols.

Conclusions: The lack of correlation indicates that measurement of CD36 levels in plasma is not trivial. The two commercial assays are not appropriate for CD36 detection in plasma and it seems unlikely that the established pathophysiological association with elevated plasma CD36 can be reproduced.


Corresponding author: Simon Lykkeboe, MSc, Department of Clinical Biochemistry, Aalborg Hospital, Aarhus University Hospital, Hobrovej 18-22, 9000 Aalborg, Denmark Phone: +45 9932 28034

Received: 2011-08-09
Accepted: 2012-1-4
Published Online: 2012-02-03
Published in Print: 2012-06-01

©2012 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Masthead
  2. Masthead
  3. Editorial
  4. Laboratory maternal-fetal medicine: challenges and perspectives
  5. Reviews
  6. Candidate biochemical markers for screening of pre-eclampsia in early pregnancy
  7. Linking preeclampsia and cardiovascular disease later in life
  8. Mini Reviews
  9. Fetal nucleic acids in maternal blood: the promises
  10. Ethical aspects of the expansion of neonatal screening programme due to technological advances
  11. Prenatal screening for trisomy 21: recent advances and guidelines
  12. Ultrasound markers for the detection of women at risk of developing pre-eclampsia
  13. Are biological markers relevant for the diagnosis and the prognosis of preterm premature rupture of membranes (PPROM)?
  14. Genetics and Molecular Diagnostics
  15. Study of FTMT and ABCA4 genes in a patient affected by age-related macular degeneration: identification and analysis of new mutations
  16. Rapid detection of CFH (p.Y402H) and ARMS2 (p.A69S) polymorphisms in age-related macular degeneration using high-resolution melting analysis
  17. Unlabeled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in pancreatic adenocarcinoma tissues
  18. General Clinical Chemistry and Laboratory Medicine
  19. Volume, rates, source and types of add-on pathology test requests across five hospitals
  20. Schizophrenia is associated with increased levels of serum Fas and FasL
  21. Comparison between capillary, venous and arterial levels of protein S100B in patients with severe brain pathology
  22. Changes of serum adiponectin and soluble intercellular adhesion molecule-1 concentrations after smoking cessation
  23. Lack of consistency between two commercial ELISAs and against an in-house ELISA for the detection of CD36 in human plasma
  24. Comparison of a commercial urinary neopterin radioimmunoassay with high performance liquid chromatography
  25. Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin
  26. Analytical performance evaluation of four cartridge-type blood gas analyzers
  27. Cancer Diagnostics
  28. Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation
  29. Cardiovascular Diseases
  30. Homocysteine as a determinant of left ventricular ejection fraction in patients with diabetes
  31. Plasma total homocysteine is a determinant of carotid intima-media thickness and circulating endothelial progenitor cells in patients with newly diagnosed hypertension
  32. Serum MMP-9 and TIMP-1 concentrations and MMP-9 activity during surgery-induced inflammation in humans
  33. Effects of endothelin-1 on endothelial progenitor cell function
  34. Investigation of cystatin C and cystatin C based estimated glomerular filtration rate in pregnant patients with heart failure
  35. Letters to the Editor
  36. Comments on a performance evaluation of cartridge-type blood gas analyzers
  37. Comments on a performance evaluation of cartridge-type blood gas analyzers. Reply
  38. Carryover can be a cause of false-positive results with the Beckman AccuTnI assay
  39. Method comparison of a 25-hydroxy vitamin D enzyme immunoassay to liquid chromatography tandem mass spectroscopy
  40. Bone marrow plasma cell separation – validation of separation algorithm
  41. Sharing our experience in improving postgraduate clinical biochemistry training with laboratory practice articles
Downloaded on 17.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2011-0950/html
Scroll to top button